Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
OSKIRA-ABPM: A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Arthritis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female patients aged 18 or over diagnosed with rheumatoid arthritis after the age of 16
Active rheumatoid arthritis defined as: ≥4 swollen joints and ≥4 tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate ≥28 mm/h, or C-reactive protein ≥10 mg/L.
Currently taking one of the following disease-modifying anti-rheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine.
Patients without essential hypertension or with essential hypertension if their blood pressure is controlled (\<140/90 mmHg) with anti-hypertensive medications being stable at least 4 weeks prior to randomisation.
You may not be if
Females who are pregnant or breastfeeding.
Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders
History of liver problems that have required previous investigations
Evidence of tuberculosis infection
Conditions that preclude or render difficult the 24-hour ambulatory blood pressure monitoring technique.
